Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)
Summary: Calcitonin-gene-related peptide (CGRP) plays a key role in migraine pathophysiology. Aimovig (erenumab; erenumab-aooe in the United States) is the only US Food and Drug Administration (FDA)-approved monoclonal antibody (mAb) therapy against the CGRP receptor (CGRPR) for the prevention of mi...
Main Authors: | Fernando Garces, Christopher Mohr, Li Zhang, Ching-Shin Huang, Qing Chen, Chadwick King, Cen Xu, Zhulun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-02-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124720300383 |
Similar Items
-
The role of erenumab in the treatment of migraine
by: Anna P. Andreou, et al.
Published: (2020-05-01) -
Erenumab in Mechanism-based Migraine Treatment
by: Aynur Özge, et al.
Published: (2021-09-01) -
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
by: Bianca Raffaelli, et al.
Published: (2019-06-01) -
MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
by: Robert Belvís, et al.
Published: (2021-07-01) -
Efficacy and safety of erenumab in the preventive treatment of migraine in adults: a systematic review
by: Yan LIN, et al.
Published: (2018-09-01)